Lack of progress in cardiogenic shock: Lessons from the GUSTO trials

Venu Menon, J. S. Hochman, A. Stebbins, M. Pfisterer, J. Col, R. D. Anderson, D. Hasdai, David Holmes, E. R. Bates, E. J. Topol, R. M. Califf, E. M. Ohman

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Aims: We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s. Methods and Results: GUSTO-I (1990-1993) and GUSTO-III (1995-1997) prospectively identified all patients with cardiogenic shock complicating acute myocardial infarction. Demographics, clinical presentation and outcomes for cardiogenic shock patients in the two trials were compared. Only patients enrolled with cardiogenic shock in countries common to both trials were included in these analysis. The 695 patients with cardiogenic shock in GUSTO-III were compared with the 2814 patients with cardiogenic shock in GUSTO-I. GUSTO-III patients were older (P=0.0001) and more likely to be diabetic (P=0.009) and hypertensive (P=0.025). They had a higher Killip class (P=0.002) and significantly greater index anterior infarction than cardiogenic shock patients enrolled in GUSTO-I. Time to treatment, presentation heart rate, and diastolic blood pressure were similar; however, systolic blood pressure at presentation was higher among GUSTO-III patients (P=0.002). Rates of coronary angiography, pulmonary artery catheterization, and mechanical ventilation declined in GUSTO-III compared with GUSTO-I (P=0.001); rates of angioplasty and bypass surgery were similar. Cardiogenic shock mortality in GUSTO-III was significantly higher than in GUSTO-I (62 vs 54%, P=0.001), as were rates of reinfarction (14 vs 11%, P=0.013) and recurrent ischaemia (35 vs 27%, P=0.00001). Mortality at non-U.S. sites (68 and 64%) was higher than at U.S. sites (53 and 50%) in both GUSTO-I and GUSTO-III studies, respectively. Angioplasty, bypass surgery, and balloon pump rates were lower for non-U.S. patients. Conclusions: Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients. Lower mortality observed in the U.S.A. supports consideration for percutaneous and surgical revascularization. (C) 2000 The European Society of Cardiology.

Original languageEnglish (US)
Pages (from-to)1928-1936
Number of pages9
JournalEuropean heart journal
Volume21
Issue number23
DOIs
StatePublished - Jan 1 2000

Fingerprint

Cardiogenic Shock
Blood Pressure
Mortality
Angioplasty
Swan-Ganz Catheterization
Coronary Angiography
Artificial Respiration
Infarction
Ischemia
Heart Rate
Myocardial Infarction
Demography
Databases

Keywords

  • Mortality
  • Myocardial infarction
  • Shock
  • Thrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Menon, V., Hochman, J. S., Stebbins, A., Pfisterer, M., Col, J., Anderson, R. D., ... Ohman, E. M. (2000). Lack of progress in cardiogenic shock: Lessons from the GUSTO trials. European heart journal, 21(23), 1928-1936. https://doi.org/10.1053/euhj.2000.2240

Lack of progress in cardiogenic shock : Lessons from the GUSTO trials. / Menon, Venu; Hochman, J. S.; Stebbins, A.; Pfisterer, M.; Col, J.; Anderson, R. D.; Hasdai, D.; Holmes, David; Bates, E. R.; Topol, E. J.; Califf, R. M.; Ohman, E. M.

In: European heart journal, Vol. 21, No. 23, 01.01.2000, p. 1928-1936.

Research output: Contribution to journalArticle

Menon, V, Hochman, JS, Stebbins, A, Pfisterer, M, Col, J, Anderson, RD, Hasdai, D, Holmes, D, Bates, ER, Topol, EJ, Califf, RM & Ohman, EM 2000, 'Lack of progress in cardiogenic shock: Lessons from the GUSTO trials', European heart journal, vol. 21, no. 23, pp. 1928-1936. https://doi.org/10.1053/euhj.2000.2240
Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD et al. Lack of progress in cardiogenic shock: Lessons from the GUSTO trials. European heart journal. 2000 Jan 1;21(23):1928-1936. https://doi.org/10.1053/euhj.2000.2240
Menon, Venu ; Hochman, J. S. ; Stebbins, A. ; Pfisterer, M. ; Col, J. ; Anderson, R. D. ; Hasdai, D. ; Holmes, David ; Bates, E. R. ; Topol, E. J. ; Califf, R. M. ; Ohman, E. M. / Lack of progress in cardiogenic shock : Lessons from the GUSTO trials. In: European heart journal. 2000 ; Vol. 21, No. 23. pp. 1928-1936.
@article{74393b59e21243d794c70c2cb109491e,
title = "Lack of progress in cardiogenic shock: Lessons from the GUSTO trials",
abstract = "Aims: We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s. Methods and Results: GUSTO-I (1990-1993) and GUSTO-III (1995-1997) prospectively identified all patients with cardiogenic shock complicating acute myocardial infarction. Demographics, clinical presentation and outcomes for cardiogenic shock patients in the two trials were compared. Only patients enrolled with cardiogenic shock in countries common to both trials were included in these analysis. The 695 patients with cardiogenic shock in GUSTO-III were compared with the 2814 patients with cardiogenic shock in GUSTO-I. GUSTO-III patients were older (P=0.0001) and more likely to be diabetic (P=0.009) and hypertensive (P=0.025). They had a higher Killip class (P=0.002) and significantly greater index anterior infarction than cardiogenic shock patients enrolled in GUSTO-I. Time to treatment, presentation heart rate, and diastolic blood pressure were similar; however, systolic blood pressure at presentation was higher among GUSTO-III patients (P=0.002). Rates of coronary angiography, pulmonary artery catheterization, and mechanical ventilation declined in GUSTO-III compared with GUSTO-I (P=0.001); rates of angioplasty and bypass surgery were similar. Cardiogenic shock mortality in GUSTO-III was significantly higher than in GUSTO-I (62 vs 54{\%}, P=0.001), as were rates of reinfarction (14 vs 11{\%}, P=0.013) and recurrent ischaemia (35 vs 27{\%}, P=0.00001). Mortality at non-U.S. sites (68 and 64{\%}) was higher than at U.S. sites (53 and 50{\%}) in both GUSTO-I and GUSTO-III studies, respectively. Angioplasty, bypass surgery, and balloon pump rates were lower for non-U.S. patients. Conclusions: Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients. Lower mortality observed in the U.S.A. supports consideration for percutaneous and surgical revascularization. (C) 2000 The European Society of Cardiology.",
keywords = "Mortality, Myocardial infarction, Shock, Thrombolysis",
author = "Venu Menon and Hochman, {J. S.} and A. Stebbins and M. Pfisterer and J. Col and Anderson, {R. D.} and D. Hasdai and David Holmes and Bates, {E. R.} and Topol, {E. J.} and Califf, {R. M.} and Ohman, {E. M.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1053/euhj.2000.2240",
language = "English (US)",
volume = "21",
pages = "1928--1936",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "23",

}

TY - JOUR

T1 - Lack of progress in cardiogenic shock

T2 - Lessons from the GUSTO trials

AU - Menon, Venu

AU - Hochman, J. S.

AU - Stebbins, A.

AU - Pfisterer, M.

AU - Col, J.

AU - Anderson, R. D.

AU - Hasdai, D.

AU - Holmes, David

AU - Bates, E. R.

AU - Topol, E. J.

AU - Califf, R. M.

AU - Ohman, E. M.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Aims: We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s. Methods and Results: GUSTO-I (1990-1993) and GUSTO-III (1995-1997) prospectively identified all patients with cardiogenic shock complicating acute myocardial infarction. Demographics, clinical presentation and outcomes for cardiogenic shock patients in the two trials were compared. Only patients enrolled with cardiogenic shock in countries common to both trials were included in these analysis. The 695 patients with cardiogenic shock in GUSTO-III were compared with the 2814 patients with cardiogenic shock in GUSTO-I. GUSTO-III patients were older (P=0.0001) and more likely to be diabetic (P=0.009) and hypertensive (P=0.025). They had a higher Killip class (P=0.002) and significantly greater index anterior infarction than cardiogenic shock patients enrolled in GUSTO-I. Time to treatment, presentation heart rate, and diastolic blood pressure were similar; however, systolic blood pressure at presentation was higher among GUSTO-III patients (P=0.002). Rates of coronary angiography, pulmonary artery catheterization, and mechanical ventilation declined in GUSTO-III compared with GUSTO-I (P=0.001); rates of angioplasty and bypass surgery were similar. Cardiogenic shock mortality in GUSTO-III was significantly higher than in GUSTO-I (62 vs 54%, P=0.001), as were rates of reinfarction (14 vs 11%, P=0.013) and recurrent ischaemia (35 vs 27%, P=0.00001). Mortality at non-U.S. sites (68 and 64%) was higher than at U.S. sites (53 and 50%) in both GUSTO-I and GUSTO-III studies, respectively. Angioplasty, bypass surgery, and balloon pump rates were lower for non-U.S. patients. Conclusions: Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients. Lower mortality observed in the U.S.A. supports consideration for percutaneous and surgical revascularization. (C) 2000 The European Society of Cardiology.

AB - Aims: We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s. Methods and Results: GUSTO-I (1990-1993) and GUSTO-III (1995-1997) prospectively identified all patients with cardiogenic shock complicating acute myocardial infarction. Demographics, clinical presentation and outcomes for cardiogenic shock patients in the two trials were compared. Only patients enrolled with cardiogenic shock in countries common to both trials were included in these analysis. The 695 patients with cardiogenic shock in GUSTO-III were compared with the 2814 patients with cardiogenic shock in GUSTO-I. GUSTO-III patients were older (P=0.0001) and more likely to be diabetic (P=0.009) and hypertensive (P=0.025). They had a higher Killip class (P=0.002) and significantly greater index anterior infarction than cardiogenic shock patients enrolled in GUSTO-I. Time to treatment, presentation heart rate, and diastolic blood pressure were similar; however, systolic blood pressure at presentation was higher among GUSTO-III patients (P=0.002). Rates of coronary angiography, pulmonary artery catheterization, and mechanical ventilation declined in GUSTO-III compared with GUSTO-I (P=0.001); rates of angioplasty and bypass surgery were similar. Cardiogenic shock mortality in GUSTO-III was significantly higher than in GUSTO-I (62 vs 54%, P=0.001), as were rates of reinfarction (14 vs 11%, P=0.013) and recurrent ischaemia (35 vs 27%, P=0.00001). Mortality at non-U.S. sites (68 and 64%) was higher than at U.S. sites (53 and 50%) in both GUSTO-I and GUSTO-III studies, respectively. Angioplasty, bypass surgery, and balloon pump rates were lower for non-U.S. patients. Conclusions: Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients. Lower mortality observed in the U.S.A. supports consideration for percutaneous and surgical revascularization. (C) 2000 The European Society of Cardiology.

KW - Mortality

KW - Myocardial infarction

KW - Shock

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0033679339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033679339&partnerID=8YFLogxK

U2 - 10.1053/euhj.2000.2240

DO - 10.1053/euhj.2000.2240

M3 - Article

C2 - 11071798

AN - SCOPUS:0033679339

VL - 21

SP - 1928

EP - 1936

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 23

ER -